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Recent advances in biological, chemical and medical disciplines are now
providing a betten understanding of the processen whereby the co ►n-
plexes of gold exercise their physiological and pharmacological effects.
As a result, exciting new developments in their therapeutic applications
are occurring and others appear likely in the future.
The unique therapeutic effects of gold compounds
can be related to their chemical properties. As one of
the group IB transition metals, gold forms a large
number of coordination complexes. In monovalent or
aurous form which is the valence form in all the
therapeutically active gold compounds in current use,
gold coordinates inter alia with sulphur- and
phosphorus-containing ligands. In the case of the
widely used drug disodium aurothiomalate (GST),
the gold is coordinated with the sulphur in the
thiomalate ion. In some recently developed drugs,
however, the gold is coordinated or bonded to both
sulphur and phosphorus. This is the case in AURANOrw
(AF) which is 2,3,4,6-tetra-O-acetyl-l-thio-/3-
D-glucopyranosato-S-triethylphosphinegold(I).
Compounds of gold such as GST and AF, like certain
anti-tumor platinum compounds such as cis-diammine-
dichloroplatinum(II) or CDDP, appear to owe their
therapeutic potential not only to the esse with which
they are transported in the body, but also to the oc-
currence of ligand exchange reactions, which result in
a blocking or re-direction of biochemical reactions
associated with certain diseases (1)
Such ligand exchange reactions can occur for exam-
ple with the amino acid cysteine which is a unit in the
structures of a variety of enzymes and other proteins
exercising important biological functions (Table I). In
its exchange reactions with aurous complexes it is the
reactive sulphydryl group (SH) of cysteine which is
involved. The cysteine is converted to its gold mer-
captide thus:
R-SH —^ R-SAu	 (1)





> Enz. -SAu + HS.CH(000Na)2	(2)
enzyme gold sodium thiomalate
mercaptide
(inactive)
As a result of its conversion to its gold mercaptide the
enzyme loses its catalytic activity, and biological reac-
tions dependent upon this activity are inhibited or
blocked.
Table 1
Aurous Derivatives of Crystalline Proteine and Enzymes. In part after (20) and (23)
Gold labelling 	 Frotein or	 I Molecular I	 Gold binding
agent	 enzyme	 weight	 sites
Au(CN)Z flavodoxin 15 000 cys 128 (cys 53)
carbonic anhydrase 30000 his 128/H20
liver alcohol dehydrogenase 80 000 cys 240 (adenine hydrophobic pocket)
Aulq Bence-Jpnes protein (part of an immunoglobulin) 12 500 ?
myoglobin 17 000 close to the haem group
chynotrypsin 25 300 7
AuSNa2C4H304 l3 glucuronidase — probably SH reactive sites
(gold sod um cathepsin-D — probably SH reactive sites
thiomalate) succinic dehydrogenase — probably SH reactive sites
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Table li
Comparison of the Fffeets of Suiphydryl-Blocking Agents on Lysosoinal Enzyme. Activity
Enzyme inhibition, per cent
Inhibitor Inhibitor/suiphydryl molar ratio
0.01 0.05	 0.1	 1.0 10	 25
N-Ethylmaleimide (NEM) — — 10 25 28 —
p-Chloromercuribenzene sulfonic acid (pCMBS) 7 9 10 25 42 —
Gold sodium thiomalate 12 20 25 27 30 —
Silver nitrate — — 31 40 51 —
Gold chloride — — 30 41 55 —
lodoacetamide — — — — — 38
Certain detrimental reactions performed by en-
zymes and which will be described below, appear to
contribute to or result in pathobiological processes of
connective tissue disorders such as rheumatoid ar-
thritis. Inflammation and misdirected immunological
activity (auto-immunity) are the hallmark of these
disorders. The underlying pathobiology is
characterized to a major extent by lysosomal enzyme
action detrimental to the articular structures. Such ac-
tion can, however, be inhibited by complexes of gold
or other sulphydryl-blocking agents (Table II).
A possible contributing factor to connective tissue
disorders such as rheumatoid arthritis is the depletion
of protein sulphydryl groups (2 to 5) arising from an
apparent failure of metabolic redox mechanisms to
reverse tissue sulphydryl oxidation. This effect is ac-
centuated by the inflammatory process of superoxide
formation. Protein sulphydryl oxidation can result in
protein disulphide interchanges and ensuing altera-
tions in native protein structure:
ASH HS > S S
SH S SH HS (3)S
SH S S S —
where A is the tissue SH oxidation brought about by
oxygen or superoxide and B the intermolecular SH-
disulphide interchange.
Such changes in conformational (autologous) pro-
tein structure are likely to elicit destructive im-
munological responses directed against the altered
protein. Blockage of protein sulphydryl groups by
gold as in the equation:
	SH 	 HS	 SAu AuS
Au
	
— SH	 S	 Complex SAu	 S	 (4)
	
SH	 I	 SAu
and avoidance by this means of the sulphydryl oxida-
tion and disulphide interchange reactions (6) il-
lustrated in equation (3) should prevent such
deleterious effects as those which result, for example,
from the denaturation of human gammaglobulin.
This latter reaction has been shown to occur in the in-
flamed joints of rheumatoid subjects, apparently as a
result of lysosomal enzyme action. Articular damage
is perpetuated by alteration of gammaglobulin and
other tissue components and this elicits an immune
response, such as the formation of an antibody called
rheumatoid factor (autoantibody) directed against
Table 111
Major Ceils of the Lnmune System and their Functions
Cel) type Function
T Lymphocyte cellular immunity directed against tissue grafts (transplantsl, tumors, virai,
fungal and protozoal irnmunity
Helper cell modulates and controls the Immune response
Suppressor celi modulates and controls the immune response
Memory eelt retains capacity to respond to future antigenie challenges
Killer eelt rejects grafts, tumors and 'non-self celfis
B Lymphocyte forms antibodies, primarily providing bacterial and viral immunity
Plasma celis
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Fig. 1 Schelnatic representation of evenla resulting, from an autoaggressive disease initiated and perpeluated by the
immune system utoimmune disease). The surface of the synovial living Geils is altered by the presente of antigens
JA), which causes the defender celfis (tymphoeyles and monocytes) t4 he cenfused afd attack ; The antigeus A1. are also
Joint	 y	 1 1	 p	 dies 1!C and Ib).released into the oi  fluigd wh; re the stiuiula te other cellil B , and the POdrtption 'Ofpaltt,bó• 	
formed arA ntli o i s at ^ ched to ont y ens Ei at^tr 1ct l anti oin witli complement I' w The tri 	 eon1 l xeys tlius f r	
m d eatha oc tized swallowed h eati'n cella (G and broes ht info eontaet with 1 sosonles I -1 and I b which they
normall be di ested. In the rheumatoid discase process however these owerful enz mes are released tinto the
surrounding joint (luid where they damage joint tissue
altered gammaglobulin. Alteration or denaturation of
human gammaglobulin can be prevented by the ac-
tion of sulphydryl-reactive agents such as gold,
histidine and penicillamine (6).
Altered Immune Functions and Induction
of Human Auto-immune Disorders
Alterations in the structures of native proteins trig-
ger immune responses. In rheumatoid arthritis, these
responses ultimately take the form of tissue injury
promoted by lysosomal enzymes (Figure 1). The
inaugural event may be a viral infection of the con-
nective tissues that sets into motion destructive
immuno-pathological processes in which a varied
population of lymphocytes plays a centra! role.
One must appreciate that the immune system is
responsible for distinguishing one's own tissues and
cells as `self Erom tumor cells or foreign invading par-
ticles (bacteria, viruses, fungi, etc.). This is a vitally
important task and involves many complicated in-
teractions. For the sake of brevity, two basic immune
responses are considered in relation to the
pathogenesis of rheumatoid arthritis: one that results
in the production of antibodies and one in which
white blood cells, usually lymphocytes and
monocytes, react directly with foreign substances or
tumor cells (antigens) to destroy them. This latter
response has only recently been studied and has been
found to be highly complex because several popula-
tions of lymphocytes are involved. These include, for
example, B and T cells (Figure 2), each with their
particular effector function (Table III). Moreover,
these lymphocyte populations may be further
classified into sub-populations of memory, killer,
helper and suppressor cells, with finely tuned func-
tions for the immune response. The wide variations
in reactivity of lymphocytes are thought to be
genetically conferred and can be traced to a diverse
spectrum of receptors for antigens found on the sur-
faces of these cells. These surface receptors trigger
and control the cellular processes of tolerante to 'self',
antibody production and cellular immunity, which
appear to be susceptible to modification by coor-
dinated heavy metal complexes.
Therapeutic in vivo as well as in vitro studies in-
dicate that gold binds to lymphocyte membranes and
accumulates within lymphocyte cells. The notion that
binding of gold to lymphocytes also affects the latter's
function is supported by the profound changes
observed during chrysotherapy.
The Effect of Gold on Cellular Biological
Functions
Excessive homeostatic protective mechanisms, for
instante in the febrile response and enlargement of
lymph glands during a throat infection, can result in
such swelling and tissue inflammation as to cause
greater injury than the inaugural infection. In
rheumatoid arthritis such over-reaction, in the form
of joint inflammation, perpetuates the disease process
by contributing to tissue injury that brings into play
previously described immune (autodestructive) pro-
cesses performed by lymphocytes directed against
altered or injured tissue sites (Figure 1). The
therapeutic action of gold and other sulphydryl-
reactive agents could thus be either through the in-
hibition of enzyme activity or through the prevention
of protein disulphide interchange. 1f injury by
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Fig. 2 Scanning electron
inicrograph of 'defender' white
cells involved in the defence of
the body against diseasc. The
`hairy' cella are B lymphocytes,
derived from bone marrow and
responsible for thc production
of antibodies. The 'smooth' cells
are T lymphocytes, another type
of defender cell, processed in
the thymus and involved in the
rccognition of foreign sub-
stances x 5 000
lysosomal enzyme and changes in original protein
structure are not prevented, these deleterious events
are likely to contribute to inflammation and to the im-
munological reactions described above. The authors
have indeed observed that the, hydrolytic and pro-
teolytic action of the lysosomal enzymes beta-
glucuronidase and cathepsin-D are inhibited by gold
compounds at pharmacologically achievable concen-
trations when these are added to synovial (joint) fluid
or synovial tissue taken from rheumatoid subjects and
propagated in culture (Table II and Figure 3). Inhibi-
tion by gold of lysosomal enzyme activity would thus
prevent autodigestive injury to the articular struc-
tures such as cartilage, tendon and bone.
Phagocytosis of immune complexes, a prelude to
lysosomal injury, is also inhibited by gold at phar-
macologically achievable levels (Figure 4) (7).
Fig. 3 This graph of the inhibition of acid hydrolase
activity vs. the rnolar ratio of gold to sulphydryl
groups in synovial fluid illustratcs the action of gold
sodiumn thiomalate on enzymti aëtivity
Similarly, immunological injury to the connective
tissues by lymphocytes responding to altered or
denatured protein can also be decreased by suppress-
ing lymphocyte function. Hence, suppression of a B
cell effector function would cause a decline in the pro-
duction of autoantibodies such as rheumatoid factor
and immunoglobulins (Table IV), while suppression
of T lymphocytes would lessen cellular cytotoxic
destructive processes. Indeed, we have observed,
under therapeutic conditions simulated in vitro, that
the following lymphocyte metabolic processes are in-
hibited by gold: respiration; RNA, DNA and protein
synthesis and proliferation or cloning. A unifying
hypothesis for these observations is that gold com-
pounds suppress hypermetabolic functions associated
with excessive phagocytic and lymphocytic activity.
This effect on cellular functions is reflected in the
suppression of rapid. mitochondrial respiration. We
have observed the inhibition of succinic acid
dehydrogenase and other respiratory chain enzymes
when mitochondrial preparations obtained from rats
with induced arthritis are incubated with gold com-
pounds at pharmacological concentrations. Leninger
(8) has reported that suppression of mitochondrial
respiration correlates with blocking of mitochondrial
protein sulphydryl groups following incubation with
heavy metal complexes. Thus, suppression of cellular
metabolic functions by coordinated metal complexes
suggests new therapeutic applications including the
treatment of disorders associated with excessive cell
proliferation. Notable examples are cancerous
disorders, including those of the immune system
exemplified by lymphoproliferative disorders as in
lymphomas, sarcomas, leukemias, etc.
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Fig. 4 Schematie representation of gold binding to eelt surface structures.lantigens and antigen receptors) to inhibit
their interactions. Gold also binds to antigens and immune complexes which ultimately blocks phagocytosis and
inhibits the lysosomal enzyme release and activity depicted in Figure 1
Applied Gold Therapy
Some of the current theories and observations per-
taining to the pathobiology of rheumatoid arthritis
and related disorders have been reviewed briefly. The
misdirected or aberrant immunological response is,
no doubt, a major contributor to the inflammation
and damage sustained by the joints and the connec-
tive tissues. The final expression of this injury, as we
have indicated, results from a complicated series of
biochemical events that can be partially or totally in-
hibited by complexes of heavy metals such as gold
(sec equation (1) and Figure 4).
The goal of therapy is to inhibit or reverse the
pathobiological events that result in tissue injury and
inflammation. If based on gold, such therapy may be
double-edged because it can also inhibit essential
biochemical processes and thereby cause serious and
even lethal adverse reactions. Hence, as is often the
case with drug therapy, a difficult course has to be
followed in order to achieve success.
Historical Aspects of Chrysotherapy
Gold was used for therapeutic applications by the
ancient Egyptian and Chinese civilizations and
possibly even earlier. It is doubtful, however, whether
the elemental gold then used was at all active or effec-
tive. In contrast, the solutions prepared by alchemists
by dissolution of gold in aqua regia were $o active and
highly toxic that their use was normally by topical ap-
plication in the treatment of disorders such as
leprosy.
With the discovery by Pasteur in the late 19th cen-
tury of micro-organisms and of their causative role in
infectious human diseases, chemotherapy evolved as
the art of using an agent that would selectively inhibit
or destroy infectious organisms without at the same
time harming their human hosts. Gold cyanide was
observed by Dr. Robert Koch to inhibit the growth of
tubercle bacilli, while success with other metal
derivatives (Ehrlich's magie bullets) was reported in
the treatment of syphilis. These observations en-
couraged a search for `gold bullets' for the treatment
of rheumatoid arthritis which was initially also
throught to be caused by infection with the strep-
tococcus.
It is probably the fortuitous use of gold complexes
by Landé and the improvement of articular
manifestations in patients with tuberculosis and coin-
cident rheumatoid arthritis that led Forestier in 1929
to use such complexes specifically for the treatment of
rheumatoid arthritis (9). He was able to confirm the
benefits of gold therapy, but serious toxic and
sometimes fatal reactions were associated with ad-
ministration of the gold complexes which he studied
and the resulting apprehension understandably
limited their use. Subsequently, the use of gold-
sulphur complexes was found to be safer though con-
cern regarding their toxicity influenced their dosage
and the frequency of their administration. The Jatter
were empirical and the aim was to avoid toxicity
while at the same time retaining efficacy. It is not sur-
prising that confusion regarding the efficacy of gold
compounds for the treatment of rheumatoid arthritis
persisted until the late 1950's when a carefully con-
ducted multi-centre study controlled by the Empire
Rheumatism Council established that gold was an ef-
fective agent with remittive potential (10). Even after
this detailed study, dosage was limited to one 50 mg
injection per week for a 20-week period and then
usually discontinued for fear of cumulative toxicity.
At that time the custom was not to exceed an ac-



















WEEKS AFTER INJECflON 
Fig. S l-lourly and daily blood serum gold (as Au) values following the administration of 50 nng gold sodium thionialate
to patients at the 20th week of treatment (left) and schematic pattern of }lood gold availability during the ensuing 4
weeks (right). With conventional therapy, administration of gold is discontinued after the 20th injection and blood
seruni gold values fall below the zone of bioavailability witpin days, Witli individualized or adjusted therapy, tbc
treatment is maintained ad weekly administration of gold, which is monitored by blood gold determinations,
facilitates bioavailability
high relapse rate of disease it was later decided on an
empirical basis to continue 'maintenance therapy'
with 50 mg of GST administered monthly. With in-
creasing knowledge of modern pharmacokinetics and
wider experience, gold therapy has become safer and
more effective in the treatment of rheumatoid ar-
thritis. Recently, moreover, other serious medical
disorders that seem to share common disturbances of
immune function, resulting in injury'to the connec-
tive tissues including articular structures as described
earlier, have also been treated `with gold compounds.
To date, however, gold therapy is still largely ad-
ministered on an empirical rather than individualized
regimen.
Gold Administration — Blood Level Response
The development of atomic absorption spec-
trophotometry has made possible rapid and accurate
analysis for gold in blood and other tissues (11). Infor-
mation gained from blood gold analysis by this
technique has been applied by the authors in an at-
tempt to improve the current empirically based mode
of gold administration. The effects of dosage, fre-
quency and duration of gold administration were
studied and relationships between blood gold concen-
trations and distribution of gold to plasma proteins,
cellular blood components and other tissues were
observed. After noting correlations between blood
gold (as Au) levels and clinical response, adverse reac-
tions and changes in specific laboratory parameters
including the effects on immune function, this infor-
mation was consolidated in the formulation of a
therapy schedule (12). Gold administration
monitored by blood gold level could then be in-
dividualized, adjusted and continued weekly to main-
tain a specified range of gold (as Au) concentration in
the blood (300 to 700 pg/dl).
Variations in Patients' Blood Gold Levels
The serum gold concentration and subsequent
decay patterns following a 50 mg injection of GST
are shown in Figure 5. Moderate individual varia-
tions in both peak levels and subsequent daily values
are not uncommon. Thus, patients 'sensitive' to gold,
who constitute approximately 10 per cent of the total,
respond with rather high serum gold levels; a pattern
that usually persists throughout the course of therapy.
Conversely, in another 10 per cent of the patients,
after the same 50 mg intramuscular dose of GST,
blood gold levels above 300 µg/dl are often not sus-
tained. These patients require, and receive, larger
doses to maintain blood gold levels in the indicated
range of `bioavailability'. We postulate that dif-
ferences observed in serum gold response may be due
to differing rates of distribution, retention and excre-
tion of gold. These rates are possibly affected by
variations in gold ligands, such as cysteine and
histidine, to which the GST is exposed after it has
been administered.
Therapeutic Response
Through experience gained in monitoring blood
gold levels, it was established that gold administration
need not arbitrarily be curtailed after 20 weekly injec-
tions, as is customary with the empirical regimen if a
beneficial response is not achieved. Conversely, when
a successful response is achieved, individualized ad-
ministration can avoid the high relapse rate and
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Table IV
Changes in Lahoratory Parameters in Patients Receiving Individuaiized Gold Sodium Thiornalate
^GST) Chrysotherapy
Parameter	 I Normai range I 	 Years of therapy
`	 admission (	 1	 I	 • 2
Number of subjects 39 39 23 16 10
IgA, mg/dl 50 to 400 325±39(a) 213±21(c) 249±42(e) 233±54(d) 251±109
19G, mg/dl 600 to 2000 1494±75 1228±71(d) 1229±132(e) 1134±134(d) 1002±88(d)
I.gM, mgldi 20 to 200 130±16 77±8(c) 65±8(c) 61±9(d) 63±13(e)
Rheumatold factor titer
(reciprocal tube dilutións) 8.6±0.3 4.6±0.6(c) 3.8±0.8(c) 3.4±1,0(d) 3:0±1.5(e)
(Erythrocyte sedimentation.
rata ESR, Wintrobe), mm/hour 20 37.7±2.1(b) 25:1±2 0(c) 24,3±2.6(c) 28.6.±3.6(e) 32.1±6.0
.Leukocytes/mm3 4100 to 10900 7752±275(b) 6859±279(c) 6281±292(c) 6763±4390 6836±706
Lymphocytes/mm3 820 to 2180 1921±93(b) 1618±101 1583±93(c) 1449±76(c) 1419±192(e)
Cumulative dose GST, mg
Meen 0* 2106 3993 5309 8747
Range 0* 1065 to 2885 2635 to 5560 4760 to 7735 5385 to 15160
±Standard error of the .meen (SEM)




(d) P < 0.01	 by paired variate 't' statistics
(e)P<0.05
The change in values and/or decline in statistical signiflcance after the second geer resuited from loss of the best rasponders who achieved
remission
disease exacerbation often encountered as the
frequency of injections is curtailed with empirical
dosing. An added advantage of weekly dosing on the
basis of blood gold levels is that gold administration
can be sustained in order to achieve a stisfactory
clinical response, which may require 18 months or
more (13,14). Concern regarding cumulative gold
toxicity, if the 300 to 700 µg/dl range is not exceeded,
has largely been dispelled by comprehensive
laboratory assessments that were made while weekly
gold therapy was continued for more than 5 years.
Cumulative doses in excess of 15 g GST have been
administered without evidente of cumulative toxicity
or adverse reactions. So far, the dreaded problem of
bone marrow toxicity has not been encountered in
more than 150 subjects who have received indivi-
dualized chrysotherapy. (Thrombosytopenia has been
observed with individualized therapy and is feit to be
an idiosynchratic rather than a toxic reaction since
bone marrow damage was not detected by
microscopic examination). Incidente of gold der-
matitis, which usually does not dictate termination of
gold therapy, and incidente of renal injury, which
does require termination of therapy, are approximate-
ly the same as with the empirical regimen. Based on
blood gold levels and gold excretion, these adverse
reactions appear to be manifestations of idiosynchrasy
rather than toxicity.
The observations reported here have created in the
medical literature some controversy regarding the
validity of individualized therapy and the significance
of blood gold levels (15,16). Conflicting studies,
however, utilized fixed rather than individualized
dosage and this was not continued weekly for the ex-
tended treatment interval instituted by the authors of
this article. According to the latter's experience, in-
dividualized chrysotherapy has yielded significantly
greater clinical benefits and these have correlated
with the suppression of several laboratory im-
munological parameters. Thus, the levels of lym-
phocyte counts, immunoglobulins and the
rheumatoid factor which are thought to contribute
to the pathogenesis of the disease have all declined
(Table IV).
Gold Kinetics — Delivery and Tissue
Distribution
How is gold delivered to the target or effector sites
active in the pathobiology of rheumatoid arthritis?
Factors influencing gold distribution may include:
(1) Mass action, for which the concentrations of gold
complex in the blood and the extent to which
these are sustained are important
(2) The nature of the gold complex. For example, it
may be hydrophobic or hydrophilic and ionic or
non-ionic. Its properties may affect cellular mem-
brane penetration
(3) The stability of the gold complex, and in par-
ticular whether it remains intact or whether the
organic ligands bonded to the gold are degraded.
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Fig. 6 Schematic representa.tion of the
nechanisni of enzyme activity inhibition by
;old and its relationship with blood serum
;old (as Au) valces. Individualized
;hrysotherapy aims at maintain.ing these















LO F COMPLEXCONTAINING AU
Aurous complexes bind readily on a mass action basis
to blood proteins, formed elements and other tissue
components. Therefore, these compete for gold with
effector sites. Moreover, gold-sulphur and gold-
phosphorus compounds such as GST and AF have
limited stability which would seem to dictate frequent
administration to facilitate distribution of the active
agent to potential efTector sites (Figure 6). We
postulate that the enhanced response achieved by con-
tinuing weekly administration may be related to the
more frequent and higher peaks achieved in serum
gold content (Figure 5). During these peaks, greater
availability of the active agent would be predicted;
2238CPM	 126 CPMJ
Fig. 7 Distribution ot gold-198 on several serum pro-
tein components and I-complex fraction (20.32 S) at
var ous pharmacological serum gold levels. The
coneentration ranges of the proteins veere:
.IgC: 990 to 1120 mg/dl
IgA: 245 to 280 mg/d1
IgM: 89 to 102 mg/dl
fl 1C: 110 to 135 mg/dl.
3.43 x 105 cpm are equivalent to 1 pg of gold•198.
The experimental data were corrected for decreas-
ing isotope activity before. plotting. After (17)
improved distribution in tissue would facilitate bind-
ing to reactants in the inflammatory and immune
system at effector sites (Figure 4). Bioavailability in
excess of 300 Mg/dl appears to be required for binding
of gold to immune complexes and lymphocytes
(Figure 7) (17). When these conditions for
bioavailability of the gold are sustained through ade-
quate dosing, parameters such as immunoglobulins,
rheumatoid factor titer and lymphocyte counts appear
to respond to dosages (Table IV). Similarly, other
pathobiological mechanisms — the inhibition of acid
hydrolases and the suppression of phagocytic activity
— are dependent on the bioavailability of the reactive
gold complex. Hence, we postulate that the availabili-
ty of gold to tissues affected by the disease process, as
for example its availability for binding to immune
complexes and lymphocytes at serum gold Ievels
greater than 300 µg/dl (Figure 6), may be an impor-
tant consideration. This concept is also supported by
in vitro studies made by other investigators and by
our observations that inhibition of Iymphocyte,
monocyte and phagocytic function was clearly depen-
dent on the concentration of aurous gold in blood
being above 300 µg/dl.
Current Progress and Future Applications
of Gold Therapy.
Gold compounds are currently considered to be
amongst the more effective and remittive agents for
the treatment of rheumatoid arthritis. Although
therapeutic applications have largely been limited to
this disorder, the use of gold-sulphur complexes has
also been reported to be beneficial in the treatment of
psoriatic arthritis and discoid lupus and more recent-
ly in the treatment of pemphigus vulgaris and bron-
chial asthma (18,19). Parameters of immune function,
as the authors and others have recently reported, are
clearly affected by chrysotherapy. Accordingly, wider
application of gold therapy for those disorders involv-
ing 'autoimmune' response, especially excessive B
cell function, can be anticipated. Indeed, these new
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Fig. 8 Relative effects with time of AURANOFINIAF) (50
to 100 pg/dl) on DNA, RNA and protein iynthesis
(PRO) in RAJI cella, as measured hy 311-thyinidine ;
3H-uridine-and 3H-leucineuptake respectivety,, AF was
added at time zero and the cella werelabelled for only
the last 2 hours of the exposure period. The decline,of
activity is relative to that in a control sample
has, for example, been shown that certain tumors
elicit an immune (B lymphocyte) response in which
the antibody covers or blocks tumor determinants
that would otherwise be attacked by killer or cytotoxic
T lymphocytes (Table III). Hence, the suppression of
a B cell function by gold compounds could prevent
the formation of such blocking antibodies and thereby
facilitate tumor destruction by the T cells.
During the past year, a new formulation in which
gold is stabilized by both sulphur and phosphorus
ligands (20) was introduced for the treatment of













Fig. 9 Relative effccts witti time of AURANOFIN (AF) (50
to 100 Eeg/dl) on DNA, RNA and protein synthesis
(PRO) in HeLa cells, as measured by 3H-thymidine,
311-uridine and 3H-leucine uptake respectively, AF was.
added at time zero and the cella were sabelled for only
the last 2 hours of the exposure period. The decline of
activity is relative to that in a control .sample:
indicates that this agent (AF) is effective in the
treatment of rheumatoid arthritis and has several
advantages over conventional gold-sulphur com-
plexes. These advantages include oral administration
and significantly lower incidence of serious adverse
reactions. The hydrophobic and non-ionic
characteristics of AF facilitate cell membrane penetra-
tion and as a result the compound affects cellular
biochemical function at lower blood concentration.
Hence, the serious adverse reactions which have been
encountered in the use of gold-sulphur complexes
available so far may be avoided.
Fig. 10 The marked surface
blebbing and rounding in this
HcLa cell is the result of a
6-hour treatment with 75 iig/dl
of AURANOFIN x 4 000
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Fig. 11 Blebbed peripheral lym-
phocytes such as these are
observed in patients receiving
AURANOFIN. They can usually be
detected after 4 to 8 weeks of
therapy and represent approxi-
mately 8 to 10 per cent of the
population. Cellular blebbing is
not observed in rheumatoid ar-
thritis subjects prior to
chrysotherapy x 5 500
In studies performed with proliferating lymphocyte
and human cancer cells (African Burkitt's lymphoma
and carcinoma of the cervix grown in the laboratory)
the authors have also observed dramatic an-
tiproliferative action by AF as reflected by the sup-
pression of DNA, RNA and protein...synthesis (21,22)
(Figures 8 and 9). We have observèd a gold dose-
dependent surface morphological change illustrated
by blebbing and pitting not only in cancer cells, but
also in lymphocytes obtained from patients receiving
AF therapy (Figures 10 and 11). These dramatic mor-
phological changes appear to reflect effects of gold
compounds additional to the suppression of im-
munological parameters described earlier. The an-
tiproliferative effect of coordinated gold complexes
may be cell cycle-dependent, that is selectively
directed toward rapidly proliferating or cloning
lymphocytes involved in the autoimmune or
autoaggressive disease process. It is also possible that
the antiproliferative action of coordinated heavy
metal complexes such as AF and CDDP exerts a
regulatory or modulating effect on the immune
response, perhaps through the antiproliferative effect
exerted on specific cloning sub-populations of T lym-
phocytes (suppressor, helper, etc.).
The therapeutic potential of heavy metal complexes
is therefore considerable and its further investigation
should prove rewarding not only for the treatment of
rheumatoid arthritis but also for that of a number of
other diseases.
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